Evaluation of the criteria for renewal of LHRH agonists in patients with prostate cancer: results of the ANAREN Study

Study number: A-ES-52014-224.A plain language summary is provided as supplementary material (available at: https://www.drugsincontext.com/wp-content/uploads/2024/05/dic.2024-2-2-Suppl.pdf).